Clinical Significance of Para-Aortic Lymph Node Dissection for Advanced or Metastatic Colorectal Cancer in the Current Era of Modern Chemotherapy

被引:25
作者
Arimoto, Atsuki [1 ]
Uehara, Keisuke [1 ]
Kato, Takehiro [1 ]
Nakamura, Hayato [1 ]
Kamiya, Tadahiro [1 ]
Nagino, Masato [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol, Nagoya, Aichi 4648601, Japan
关键词
Colorectal cancer; Para-aortic lymph node metastasis; Lymph node dissection; Modern chemotherapy; RESECTABLE LIVER METASTASES; PLUS BEVACIZUMAB; OPEN-LABEL; CETUXIMAB; OXALIPLATIN; LEUCOVORIN; RECURRENCE; RESECTION; SURGERY; FOLFOX4;
D O I
10.1159/000439547
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Surgical resection is not generally indicated for para-aortic lymph node (PALN) metastasis from colorectal cancer. However, the clinical significance of PALN dissection (PALND) in the current era of modern chemotherapy has not been fully discussed. Methods: Between November 2006 and February 2013, 14 patients underwent PALND for colorectal cancer and were proven as having pathological PALN metastasis. The median follow-up was 33.2 months. Results: Primary location was the right-colon in 2 patients, and the left-colon or rectum in 12 patients. The timing of metastasis was metachronous in 5 patients and synchronous in 9 patients. Eleven patients (79%) received perioperative aggressive modern chemotherapy. Neoadjuvant chemotherapy with targeted drugs was introduced in 9 patients (64%) and 6 patients received adjuvant chemotherapy. Recurrence after PALND occurred in 12 patients (86%). The most common site was the lung in 6 patients (43%). The 1- and 3-year disease-free survivals were 39.3 and 7.9%, respectively. The 3-year overall survival were 41.2%. Conclusion: The recurrence rate after PALND for strictly selected patients was quite high even in the current era of modern chemotherapy. However, some patients achieved long-term survival or could be cured. Therefore, we should re-evaluate the efficacy of PALND in a larger prospective study. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:439 / 444
页数:6
相关论文
共 19 条
[1]  
[Anonymous], 2014, J. Clin. Oncol, DOI DOI 10.1200/JCO.2014.32.15SUPPL.LBA3
[2]   Extensive Lymphadenectomy in Colorectal Cancer With Isolated Para-Aortic Lymph Node Metastasis Below the Level of Renal Vessels [J].
Choi, Pyong Wha ;
Kim, Hee Cheol ;
Kim, Ah Young ;
Jung, Sang Hun ;
Yu, Chang Sik ;
Kim, Jin Cheon .
JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (01) :66-71
[3]   Pathological features of rectal cancer after preoperative radiochemotherapy [J].
Dworak, O ;
Keilholz, L ;
Hoffmann, A .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 1997, 12 (01) :19-23
[4]   Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial [J].
Folprecht, Gunnar ;
Gruenberger, Thomas ;
Bechstein, Wolf O. ;
Raab, Hans-Rudolf ;
Lordick, Florian ;
Hartmann, Joerg T. ;
Lang, Hauke ;
Frilling, Andrea ;
Stoehlmacher, Jan ;
Weitz, Juergen ;
Konopke, Ralf ;
Stroszczynski, Christian ;
Liersch, Torsten ;
Ockert, Detlev ;
Herrmann, Thomas ;
Goekkurt, Eray ;
Parisi, Fabio ;
Koehne, Claus-Henning .
LANCET ONCOLOGY, 2010, 11 (01) :38-47
[5]   Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial [J].
Garufi, C. ;
Torsello, A. ;
Tumolo, S. ;
Ettorre, G. M. ;
Zeuli, M. ;
Campanella, C. ;
Vennarecci, G. ;
Mottolese, M. ;
Sperduti, I. ;
Cognetti, F. .
BRITISH JOURNAL OF CANCER, 2010, 103 (10) :1542-1547
[6]   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].
Heinemann, Volker ;
von Weikersthal, Ludwig Fischer ;
Decker, Thomas ;
Kiani, Alexander ;
Vehling-Kaiser, Ursula ;
Al-Batran, Salah-Eddin ;
Heintges, Tobias ;
Lerchenmueller, Christian ;
Kahl, Christoph ;
Seipelt, Gernot ;
Kullmann, Frank ;
Stauch, Martina ;
Scheithauer, Werner ;
Hielscher, Joerg ;
Scholz, Michael ;
Mueller, Sebastian ;
Link, Hartmut ;
Niederle, Norbert ;
Rost, Andreas ;
Hoeffkes, Heinz-Gert ;
Moehler, Markus ;
Lindig, Reinhard U. ;
Modest, Dominik P. ;
Rossius, Lisa ;
Kirchner, Thomas ;
Jung, Andreas ;
Stintzing, Sebastian .
LANCET ONCOLOGY, 2014, 15 (10) :1065-1075
[7]   A Randomized Phase II/III Trial Comparing Hepatectomy Followed by mFOLFOX6 with Hepatectomy Alone as Treatment for Liver Metastasis from Colorectal Cancer: Japan Clinical Oncology Group Study JCOG0603 [J].
Kanemitsu, Yukihide ;
Kato, Tomoyuki ;
Shimizu, Yasuhiro ;
Inaba, Yoshitaka ;
Shimada, Yasuhiro ;
Nakamura, Kenichi ;
Sato, Akihiro ;
Moriya, Yoshihiro .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (06) :406-409
[8]   Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer [J].
Kim, Mi-Sook ;
Cho, Chul Koo ;
Yang, Kwang Mo ;
Lee, Dong Han ;
Moon, Sun Mi ;
Shin, Young Joo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (48) :6091-6095
[9]   Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy [J].
Kopetz, Scott ;
Chang, George J. ;
Overman, Michael J. ;
Eng, Cathy ;
Sargent, Daniel J. ;
Larson, David W. ;
Grothey, Axel ;
Vauthey, Jean-Nicolas ;
Nagorney, David M. ;
McWilliams, Robert R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3677-3683
[10]   Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer [J].
Loupakis, Fotios ;
Cremolini, Chiara ;
Masi, Gianluca ;
Lonardi, Sara ;
Zagonel, Vittorina ;
Salvatore, Lisa ;
Cortesi, Enrico ;
Tomasello, Gianluca ;
Ronzoni, Monica ;
Spadi, Rosella ;
Zaniboni, Alberto ;
Tonini, Giuseppe ;
Buonadonna, Angela ;
Amoroso, Domenico ;
Chiara, Silvana ;
Carlomagno, Chiara ;
Boni, Corrado ;
Allegrini, Giacomo ;
Boni, Luca ;
Falcone, Alfredo .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) :1609-1618